Lazzaro Spallanzani National Institute for Infectious Diseases

Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication

Retrieved on: 
Wednesday, October 26, 2022
National Institute, Monkeypox virus, Molnupiravir, Ribavirin, Illinois Institute of Technology, Lazzaro Spallanzani National Institute for Infectious Diseases, Omicron, Disease, Risk, Phases of clinical research, Caco-2, IND, Infection, HKEX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, Investigational New Drug, NHC, Permeability, Monkeypox, WHO, Food, World, Orthopoxvirus, Sofosbuvir, Degenerative disease, Mefloquine, Region (Europe), CEO, Patent, IIT Research Institute, BioRxiv, World Health Organization, FDA, COVID-19, Atovaquone, Pharmaceutical industry, Vaccine, Technology

HANGZHOU and SHAOXING, China, Oct. 26, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the Investigational New Drug (IND) application of ASC10, an oral antiviral drug candidate targeting viral polymerase of monkeypox virus, has been filed with the U.S. Food and Drug Administration (FDA).

Key Points: 
  • ASC10 is an orally bioavailable and broad antiviral spectrum double prodrug which has a new and differentiated chemical structure from the single prodrug molnupiravir.
  • Ascletis has filed multiple patent applications globally for ASC10 and its use in viral diseases including monkeypox virus infection.
  • The data from the in vitro antiviral cellular assay with infectious monkeypox virus demonstrated that ASC10-A has potent antiviral activity against monkeypox virus, suggesting that ASC10 has the potential to be an effective treatment of monkeypox virus infection.
  • This IND filing of ASC10 for monkeypox in the U.S. will further broaden Ascletis' pipeline portfolio in viral diseases, and may provide a solution to monkeypox virus infections."

Maxwell Biosciences Raises $10.8 Million in Oversubscribed Seed Round

Retrieved on: 
Thursday, March 10, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Virus, Government, Keiretsu Forum, National Institute, NIAID, Infection, Animal, Partnership, Immune system, Therapy, DARPA, National Institute of Allergy and Infectious Diseases, Membrane, Membrane protein, Tissue, Lazzaro Spallanzani National Institute for Infectious Diseases, Entrepreneurship, MERS, List of life sciences, Peptide, Technology, NIH, Fungus, Global health, Severe acute respiratory syndrome coronavirus 2, Seed, Disease, Mycosis, Maxwell, Vaccine

Maxwell Biosciences (Maxwell") is a preclinical stage drug platform company actively developing drugs that mimic the germ-fighting properties of the innate immune system.

Key Points: 
  • Maxwell Biosciences (Maxwell") is a preclinical stage drug platform company actively developing drugs that mimic the germ-fighting properties of the innate immune system.
  • Maxwell, which develops synthetic, low molecular weight drug candidates CLAROMERS designed to serve as therapeutics against rapidly evolving, widespread viruses, today announced that it has closed an oversubscribed $10.8 million Seed Capital raise.
  • DecentraNet led the round, with participation from Star Lake Bioventures, Joseph Ventures, Keiretsu Forum and members of Harvard Business School Angels.
  • Maxwell has developed a groundbreaking drug platform technology with the potential to profoundly impact global health.

Kazakhstan becomes the first country outside Russia to authorize Sputnik M vaccine for adolescents

Retrieved on: 
Tuesday, February 22, 2022
Infection, Sputnik 1, Population, Lazzaro Spallanzani National Institute for Infectious Diseases, Ministry of Health (Russia), Ministry, Sputnik Light, Russian Direct Investment Fund, Equity, Republic, Ageing, Vaccine, Immunoglobulin G, VNA, Sputnik V COVID-19 vaccine, Vaccination, Communications satellite, Omicron, RDIF, Pfizer, COVID

Thus, Kazakhstan has become the first country outside Russia to authorize the use of Sputnik M.

Key Points: 
  • Thus, Kazakhstan has become the first country outside Russia to authorize the use of Sputnik M.
    In contrast with some international producers offering their vaccines in the same dosage for both adults and adolescents, the Gamaleya Center has developed Sputnik M specifically for adolescents.
  • Sputnik M is a two-shot vaccine based on the same human adenoviral vectors platform, which is safe and has been widely studied for over 30 years.
  • The only difference between Sputnik M and Sputnik V is a lower concentration of viral particles per dose: Sputnik M for adolescents has 5 times less concentration in comparison with the original Sputnik V in both shots.
  • Russian Ministry of Health registered Sputnik M on November 24, 2021 based on data from clinical trials confirming the high safety and immunogenicity profile of Sputnik M among adolescents.

Sputnik V is Most Used Vaccine in Mexico City, Over 3 Million People Already Given the Russian Vaccine

Retrieved on: 
Sunday, February 13, 2022
Sputnik V COVID-19 vaccine, Infection, Lazzaro Spallanzani National Institute for Infectious Diseases, Vaccine, RNA transfection, LINK, Sputnik 1, Safety, Director general, CDMX, Technology, AstraZeneca, Sputnik Light, VNA, Population, Publication, Ageing, Immunoglobulin G, Myocarditis, Pericarditis, Vaccination, City, Communications satellite, COVID, Omicron, Pfizer

The first component of Sputnik V (Sputnik Light) is also increasingly used in the city's revaccination campaign as a booster.

Key Points: 
  • The first component of Sputnik V (Sputnik Light) is also increasingly used in the city's revaccination campaign as a booster.
  • (LINK: https://www.milenio.com/politica/comunidad/sputnik-v-vacuna-rusa-utiliza... )
    City of Mexico will also extend the use of the first component of Sputnik V (Sputnik Light) as a booster for 30-39 aged group from February 14.
  • Sputnik V creates stronger and longer lasting immune response against COVID (including the Omicron variant) than many other vaccines, which is further strengthened by Sputnik Light booster.
  • Sputnik Light is based on human adenovirus serotype 26 and is the first component of Sputnik V vaccine.

Sputnik V vaccine granted full permanent approval in Russia

Retrieved on: 
Friday, February 4, 2022
Safety, List of health departments and ministries, Russian Direct Investment Fund, Coronavirus, Infection, COVID-19, Vaccination, Sputnik Light, Population, Pericarditis, V, Lazzaro Spallanzani National Institute for Infectious Diseases, Sputnik V COVID-19 vaccine, Vaccine, Immunoglobulin G, Equity, AstraZeneca, EUA, Myocarditis, Pharmaceutical industry, Omicron, Pfizer, RDIF

MOSCOW, Feb. 4, 2022 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces that the Russian Sputnik V vaccine against coronavirus has been granted full permanent approval by Russia's Health Ministry. It had previously held temporary emergency use authorization (EUA) from the Russian regulator.

Key Points: 
  • MOSCOW, Feb. 4, 2022 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces that the Russian Sputnik V vaccine against coronavirus has been granted full permanent approval by Russia's Health Ministry.
  • Sputnik V was authorized on August 11, 2020, becoming the world's first vaccine against COVID-19 to be granted emergency use authorization.
  • Sputnik V showed significantly smaller (2.6 times) reduction of virus neutralizing activity against Omicron as compared to reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold reduction for Pfizer vaccine).
  • Sputnik Light is based on recombinant human adenovirus serotype number 26 (the first component of Sputnik V).

University of Pennsylvania's School of Veterinary Medicine Establishes Institute for Infectious and Zoonotic Diseases

Retrieved on: 
Tuesday, October 26, 2021
Infection, Research, University, Vaccine, Disease, West Nile virus, Lazzaro Spallanzani National Institute for Infectious Diseases, Human, School, VMD, Gilbert, Vinlanders Social Club, Zoonosis, COVID-19, Penn, Environment, Inflammation, Awareness, Public health, DVM, Rabies, Veterinary medicine, Lyme disease, Institute, COVID, Population, Doctor of Philosophy, UC Davis School of Veterinary Medicine, New institutional economics, Animal

With 75% of all newly emerging infectious diseases being zoonotic, there is an alarming and urgent need for early detection and prevention of these threats.

Key Points: 
  • With 75% of all newly emerging infectious diseases being zoonotic, there is an alarming and urgent need for early detection and prevention of these threats.
  • The new Institute will rapidly scale up research on infectious agents and summon Penn Vet's extensive bench to tackle new or re-emerging disease.
  • The Institute will have a particular focus on diseases within the northeastern United States.
  • To learn more about the new Institute for Infectious and Zoonotic Diseases, visit http://www.vet.upenn.edu/IIZD .